deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT04440943

A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Sponsor: Celldex Therapeutics

Conditions Bladder Urothelial Carcinoma Breast Cancer Cholangiocarcinoma Esophageal Cancer Fallopian Tube Cancer Gastric Cancer Head and Neck Cancer Hepatic Cancer MSI-H Colorectal Cancer Non-small Cell Lung Cancer Other Solid Tumors Ovarian Cancer Primary Peritoneal Carcinoma Renal Cell Carcinoma
Interventions CDX-527
Updated 15 times since 2020 Last updated: Jun 16, 2023 Started: Aug 4, 2020 Primary completion: Apr 6, 2023 Completion: Apr 6, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Bladder Urothelial Carcinoma and Breast Cancer, this trial is completed. The trial is conducted by Celldex Therapeutics and has accumulated 15 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Oct 2021 · 7 months · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Apr 2023 · 4 months · monthly snapshot~Apr 2023 – ~Jul 2023 · 3 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Apr 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE1

  5. Dec 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

▶ Show 10 earlier versions

  1. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  2. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  3. Dec 2021 — Apr 2022 [monthly]

    Recruiting PHASE1

  4. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

  5. Mar 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  6. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  7. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  8. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  9. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  10. Jul 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celldex Therapeutics
Data source: Celldex Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations